JPWO2018191748A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018191748A5 JPWO2018191748A5 JP2019555484A JP2019555484A JPWO2018191748A5 JP WO2018191748 A5 JPWO2018191748 A5 JP WO2018191748A5 JP 2019555484 A JP2019555484 A JP 2019555484A JP 2019555484 A JP2019555484 A JP 2019555484A JP WO2018191748 A5 JPWO2018191748 A5 JP WO2018191748A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- cell
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014208A JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485670P | 2017-04-14 | 2017-04-14 | |
| US62/485,670 | 2017-04-14 | ||
| US201862629593P | 2018-02-12 | 2018-02-12 | |
| US62/629,593 | 2018-02-12 | ||
| PCT/US2018/027783 WO2018191748A1 (en) | 2017-04-14 | 2018-04-16 | Chimeric antigen receptor t cells targeting the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Division JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020516276A JP2020516276A (ja) | 2020-06-11 |
| JP2020516276A5 JP2020516276A5 (https=) | 2023-10-26 |
| JPWO2018191748A5 true JPWO2018191748A5 (https=) | 2023-10-26 |
| JP7505885B2 JP7505885B2 (ja) | 2024-06-25 |
Family
ID=63793633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555484A Active JP7505885B2 (ja) | 2017-04-14 | 2018-04-16 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12378297B2 (https=) |
| EP (1) | EP3609914B1 (https=) |
| JP (2) | JP7505885B2 (https=) |
| CN (1) | CN110520524A (https=) |
| AU (3) | AU2018251206A1 (https=) |
| CA (1) | CA3059444A1 (https=) |
| WO (1) | WO2018191748A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| CN110520524A (zh) | 2017-04-14 | 2019-11-29 | 综合医院公司 | 靶向肿瘤微环境的嵌合抗原受体t细胞 |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| US20210038646A1 (en) * | 2018-02-12 | 2021-02-11 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| JP2021532742A (ja) * | 2018-07-26 | 2021-12-02 | ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. | Ｎｅｆを含むｔ細胞及びその生成方法 |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| EP3947689A4 (en) * | 2019-03-27 | 2023-03-29 | National Research Council of Canada | ANTIGEN BINDING AGENTS SPECIFIC TO BINDING THE RECEPTOR VARIANT III OF THE EPIDERMAL GROWTH FACTOR |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| JP7739261B2 (ja) * | 2019-08-09 | 2025-09-16 | エイ２・バイオセラピューティクス・インコーポレイテッド | ヘテロ接合性の喪失に応答する細胞表面受容体 |
| WO2021098834A1 (zh) * | 2019-11-22 | 2021-05-27 | 上海一宸医药科技有限公司 | Psma抗体及其应用 |
| EP4073103A1 (en) | 2019-12-11 | 2022-10-19 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| CN111235113A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 包含嵌合抗原受体的免疫细胞及其用途 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| KR102859550B1 (ko) | 2020-08-20 | 2025-09-16 | 에이투 바이오쎄라퓨틱스, 인크. | Ceacam 양성 암을 치료하기 위한 조성물 및 방법 |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| TWI823402B (zh) * | 2021-07-21 | 2023-11-21 | 長聖國際生技股份有限公司 | 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物 |
| WO2023077068A1 (en) * | 2021-10-28 | 2023-05-04 | Skunkworx Bio, Inc. | Novel binding agents related to glycoprotein-a |
| WO2024192289A2 (en) * | 2023-03-14 | 2024-09-19 | The Wistar Institute Of Anatomy And Biology | Tri-specific t-cell engagers and methods of use in cancer therapeutics |
| EP4680730A2 (en) * | 2023-03-17 | 2026-01-21 | The Children's Hospital Of Philadelphia | Compositions and methods for interneuron mediated delivery of cytotoxic agents to the brain |
| CN119708251A (zh) * | 2023-09-27 | 2025-03-28 | 北京大学 | 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法 |
| WO2025076471A2 (en) * | 2023-10-04 | 2025-04-10 | Ohio State Innovation Foundation | Modulating the tumor immune microenvironment via targeting regulatory t cells (tregs) with chimeric antigen receptor (car) t cell therapy |
| WO2025092689A1 (zh) * | 2023-10-30 | 2025-05-08 | 苏州沙砾生物科技有限公司 | 一种表达多特异性抗原结合蛋白的细胞及其应用 |
| WO2025140683A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京鼎成肽源生物技术有限公司 | 表达趋化因子10和白介素15的工程化免疫细胞 |
| WO2026022768A1 (ko) * | 2024-07-24 | 2026-01-29 | (주)티카로스 | 안전하며 효과적인 유전자세포치료 시스템 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9349368B1 (en) * | 2010-08-05 | 2016-05-24 | Google Inc. | Generating an audio notification based on detection of a triggering event |
| EP2694549B1 (en) * | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| PT2961831T (pt) * | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2015015003A1 (en) * | 2013-08-01 | 2015-02-05 | Université Catholique de Louvain | Anti-garp protein and uses thereof |
| US10196608B2 (en) | 2014-02-21 | 2019-02-05 | Cellectis | Method for in situ inhibition of regulatory T cells |
| MX2017001229A (es) * | 2014-07-29 | 2017-05-01 | Pfizer | Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| JP7372728B2 (ja) * | 2014-10-31 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改変ｔ細胞に関する方法および組成物 |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| EP3256492A4 (en) | 2015-02-09 | 2018-07-11 | University of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
| EA201792573A1 (ru) * | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| US20180258149A1 (en) | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| CN105796597A (zh) | 2016-03-11 | 2016-07-27 | 江苏三特生物科技有限公司 | 携带pd-l1和ctla-4抗体基因的car-t细胞在肿瘤免疫上的应用 |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2018057915A1 (en) | 2016-09-23 | 2018-03-29 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| US20190338015A1 (en) | 2016-10-19 | 2019-11-07 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018112266A1 (en) | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| CN110520524A (zh) | 2017-04-14 | 2019-11-29 | 综合医院公司 | 靶向肿瘤微环境的嵌合抗原受体t细胞 |
| CN107326014B (zh) | 2017-07-31 | 2019-09-24 | 时力生物科技（北京）有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| EP3697820A4 (en) | 2017-10-17 | 2022-01-05 | The General Hospital Corporation | PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS |
| US20210038646A1 (en) | 2018-02-12 | 2021-02-11 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| CA3193009A1 (en) | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| WO2023081808A2 (en) * | 2021-11-04 | 2023-05-11 | The General Hospital Corporation | Anti-mesothelin car t cells secreting teams and methods of use thereof |
| CN119365202A (zh) * | 2022-04-15 | 2025-01-24 | 总医院有限公司 | 包含结合cd33的t细胞接合抗体分子的结合cd70的car-t细胞 |
-
2018
- 2018-04-16 CN CN201880025361.8A patent/CN110520524A/zh active Pending
- 2018-04-16 WO PCT/US2018/027783 patent/WO2018191748A1/en not_active Ceased
- 2018-04-16 CA CA3059444A patent/CA3059444A1/en active Pending
- 2018-04-16 EP EP18784599.5A patent/EP3609914B1/en active Active
- 2018-04-16 AU AU2018251206A patent/AU2018251206A1/en not_active Abandoned
- 2018-04-16 JP JP2019555484A patent/JP7505885B2/ja active Active
- 2018-04-16 US US16/603,675 patent/US12378297B2/en active Active
-
2023
- 2023-09-28 US US18/477,532 patent/US20240075070A1/en active Pending
- 2023-12-07 AU AU2023278069A patent/AU2023278069B2/en active Active
-
2024
- 2024-02-01 JP JP2024014208A patent/JP2024062986A/ja active Pending
-
2025
- 2025-07-08 AU AU2025205213A patent/AU2025205213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2018191748A5 (https=) | ||
| US20230399398A1 (en) | Cd7-targeting humanized antibody and use thereof | |
| EP4083073A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JP2021512635A5 (https=) | ||
| US9200078B2 (en) | Antibodies against prostate-specific stem cell antigen and use thereof | |
| EP4257610A1 (en) | Ror1-targeting antibody and use thereof | |
| JP2015513394A (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| CN110035768A (zh) | 嵌合抗原受体 | |
| JPWO2019157533A5 (https=) | ||
| US20230348556A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| CN116867805A (zh) | 一种异源二聚体蛋白质及其应用 | |
| CA3234046A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs | |
| JP2025540340A (ja) | キメラ抗原受容体 | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| US20230183351A1 (en) | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal | |
| US12371492B2 (en) | Humanized antibody specific for CD22 and chimeric antigen receptor using the same | |
| CN114763387A (zh) | 一种基于结构优化蛋白活性的三特异性抗体制备方法 | |
| WO2024008039A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| WO2022178163A2 (en) | Antibody-derived t cell activating technologies | |
| EP4613779A1 (en) | Cd24 binding protein and use thereof | |
| CN115785269B (zh) | 抗pd-l1的抗体及其应用 | |
| US20260060935A1 (en) | Therapeutic effect enhancer for enhancing effect of car-t therapy | |
| US20240018236A1 (en) | Cd19-targeting humanized antibody and use thereof | |
| JP2026513144A (ja) | Ｃｄ２４結合タンパク質およびその使用 |